A cluster of approvals and related coverage highlighted a continued push in gene therapy execution and regulatory readiness, centered on Ultragenyx’s recent Sanfilippo A approval. The FDA’s decision underscores growing comfort with one-time, vector-delivered therapies for rare neurodegenerative diseases. Together with prior manufacturer-related CRL context, the approval also signals that manufacturing reliability remains a decisive gate for these programs. The label’s safety requirements, including corticosteroid regimen timing and thrombotic microangiopathy warnings, further delineate the operational constraints for real-world treatment delivery. For the broader sector, this approval contributes to a growing body of precedents for AAV9-based gene therapy in pediatrics and can influence payer and treatment-center preparation as more programs advance into registrational phases. While other gene therapy stories appear in the broader dataset, the Sanfilippo A approval remains the most concrete regulatory step in this set.